Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NPD Beauty president

This article was originally published in The Rose Sheet

Executive Summary

NPD Beauty division VP Timra Carlson promoted to president, firm announces Jan. 28. Carlson has worked for NPD for 14 years and is credited with spearheading development of NPD BeautyTrends in 1996. As president, Carlson will be responsible for expanding NPD's beauty service internationally to provide global market research information, NPD says. Exec also will continue general management role, overseeing product development, sales and marketing for retail point-of-sale tracking service and consumer and scent testing service, company says...

You may also be interested in...



Japan's BioComo Pursues Novel Ligand Approach To Immuno-Oncology

Japan bioventure BioComo was set up around 10 years ago and has since been honing its technology platform. It is now preparing to move into the clinic with a novel vector for immuno-oncology and to raise new funds to support pipeline development.

China Uses Old To Fight New As Repurposed Drugs Take Coronavirus Role

Several newly repurposed drugs, including a Bayer antimalarial, have shown potential benefits against the new coronavirus, promoting China to add several to its latest revised treatment guidelines.

US FDA Still Seeking Sponsor Cooperation For Oncology Label Updates

Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.

UsernamePublicRestriction

Register

RS010938

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel